stockrow
Friday 6 November 2026
Export PSNL’s income statement to Excel — free account
Personalis, Inc.
PSNL Healthcare Diagnostics & Research
Personalis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $69.6 million, down 17.7% from fiscal 2024.
- Revenue
- +76.6%
- EPS
- −33.3%
- Free cash flow
- −15.5%
Quarter to September 2026, against a year earlier
15.81
0.26
+1.67%
Follow PSNL
Alert me
| Sep '26 From the 10-Q filed 4 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
21.61 | 20.28 | 10.29 | 10.20 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(64.47) | (54.82) | (29.53) | (31.93) | |
P/B ratio |
8.21 | 6.01 | 2.61 | 2.72 | |
Price to Tangible BV |
8.21 | 6.01 | 2.61 | 2.72 | |
EV/Sales |
19.47 | 17.48 | 6.95 | 7.01 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(16.12) | (13.20) | (5.64) | (6.52) | |
EV/FCF |
(14.82) | (12.08) | (5.31) | (6.15) | |
Quick Ratio |
4.23 | 4.91 | 6.31 | 6.46 | |
Current Ratio |
4.53 | 5.28 | 6.61 | 6.76 | |
Net Debt/EBITDA |
0.00 | 6.60 | 7.54 | 10.15 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.30 | 0.24 | 0.22 | 0.23 | |
Operating CF/Net income |
0.80 | 0.81 | 0.75 | 0.93 | |
Capex/Depreciation |
— | (2.81) | (2.47) | (0.05) | |
Interest Coverage |
(986.61) | (907.86) | (684.28) | (388.71) | |
Research and Development Expense of Revenue |
62.80% | 73.07% | 93.97% | 75.36% | |
Selling, General and Administrative Expense of Revenue |
101.63% | 98.39% | 115.71% | 81.26% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
15.28% | 17.81% | 16.50% | 13.25% | |
Graham Net Nets |
0.08 | 0.12 | 0.28 | 0.27 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(7.19%) | (8.13%) | (16.01%) | (11.43%) | |
Free Cash Flow Yield |
(6.08%) | (7.14%) | (12.74%) | (11.18%) | |
Revenue per Share |
0.24 | 0.21 | 0.15 | 0.19 | |
Operating CF per Share |
(0.25) | (0.24) | (0.22) | (0.25) | |
Capex per Share |
0.00 | (0.04) | (0.03) | 0.00 | |
Free Cash Flow per Share |
(0.25) | (0.28) | (0.25) | (0.25) | |
Cash per Share |
1.78 | 2.02 | 2.24 | 2.69 | |
Shareholders Equity per Share |
1.98 | 2.23 | 2.45 | 2.93 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.98 | 2.23 | 2.45 | 2.93 | |
Free Cash Flow |
(27.07) | (29.55) | (25.55) | (22.32) | |
Working Capital |
173.78 | 198.67 | 219.15 | 228.32 | |
Capital Expenditures |
— | (3.78) | (3.07) | (0.08) | |
Net Current Asset Value |
144.12 | 168.08 | 187.57 | 194.97 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.17 | 0.20 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
16.21 | 12.53 | 12.00 | 12.17 | |
Average Payables |
12.82 | 12.97 | 10.30 | 9.69 | |
Average Inventory |
6.02 | 7.54 | 5.93 | 6.04 | |
Average Assets |
267.22 | 285.41 | 299.35 | 302.22 | |
Average Common Equity |
192.04 | 213.00 | 231.06 | 232.07 |
Columns are period end dates · fundamentals updated 4 Nov 2026